Arvinas registers first-in-human Phase 1/2 trial of ARV-6723 in advanced solid tumorsAug 6Trial updateARV-6723Arvinas Inc.
Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drugAug 4Quarterly updateArvinas Inc.
Sign inSign in